Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

Phase 2positiveVortosiranPositive

AI Analysis

Summary

Ribo announced positive Phase 2a data for Vortosiran, an siRNA-mediated FXI inhibitor, in patients with coronary artery disease. This represents the first clinical data on FXI inhibition via siRNA following multiple dosing in this patient population.

Clinical Trial Data

Phase

Outcome Details

Positive data from Phase 2a trial of Vortosiran, siRNA-mediated FXI inhibition following multiple dosing in patients with coronary artery disease

Importance:6/10

Sentiment:

0.75

Phase 2 datasiRNAFXI inhibitioncoronary artery diseaseChina Pharmaceutical Innovation Conference

Related Companies

$IPIX $CHHE $TRAX $WHEN

Read the original article

Published by PR Newswire Pharma on July 22, 2026 12:30 PM

Read Original